New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
October 31, 2014
06:57 EDTINTCSkylake processor delay may weaken Windows 10 notebook demand, DigiTimes says
Subscribe for More Information
05:47 EDTINTCStocks with implied volatility movement; SMH INTC
Stocks with implied volatility movement; Market Vectors Semiconductor (SMH) 26, Intel (INTC) 26 according to iVolatility.
October 30, 2014
18:39 EDTINTCOn The Fly: After Hours Movers
Subscribe for More Information
15:28 EDTINTCIntersil sees lower sequential computing revenue as PC builds slow
Shares of Intersil (ISIL), which makes analog integrated circuits for the personal computer market, are lower after the company reported Q3 results that missed analysts' expectations. The company also gave Q4 guidance well below the consensus view for both earnings and revenue. On its earnings conference call last night, the company said it sees slowing sequential demand in part due to lower PC builds. Stocks that are leveraged to the PC sector include Intel (INTC), Texas Instruments (TXN), Advanced Micro Devices (AMD) and Microsoft (MSFT). In late day trading, shares of Intersil fell $1.81, or 12.9%, to $12.27.
12:35 EDTCOV, MDTMedtronic CEO sees Covidien merger closing in early 2015
Subscribe for More Information
10:50 EDTJNJJ&J may face additional payments of $250M on hip claims, Bloomberg says
Johnson & Johnson may have to pay an additional $250M to settle claims over the failure of its ASR hip implants, says Bloomberg. The current claims were excluded from last year's $2.5B settlement, added Bloomberg. Reference Link
07:34 EDTMDTEnteroMedics names Brad Hancock Chief Commercial Officer
Subscribe for More Information
October 29, 2014
11:08 EDTJNJOptions with increasing implied volatility: ACHN CZR ARCP HSY JNJ
Subscribe for More Information
10:17 EDTJNJGilead retreats after Hepatitis C drug sales miss expectations
Shares of drug maker Gilead (GILD) are falling after the company last night announced lower than expected third quarter profits and reported sales of its Hepatitis C treatment, Sovaldi, that came in below expectations. WHAT'S NEW: Gilead reported Q3 earnings per share of $1.84, versus analysts' consensus estimate of $1.92. The company's revenue came in slightly above expectations. Gilead said its Sovaldi drug had generated $2.8B of sales last quarter. On average, analysts had expected sales of the drug to come in at $2.93B. Sales of Sovaldi dropped 20% in Q3 versus Q2. However, the company said on its earnings conference call that the launch of its new Hepatitis C treatment, Harvoni, was off to a strong start. ANALYST REACTION: In a note to investors earlier today, Bernstein analyst Geoffrey Porges wrote that Gilead's Q3 revenue and EPS were reduced by one-time events. Its EPS would have easily beaten expectations if the company did not have to pay one-time taxes related to the Affordable Care Act, Porges stated. The lower than expected Sovaldi sales were caused by a variety of factors, including anticipation of the Harvoni launch, the analyst believes. The challenges facing Sovaldi should not affect Harvoni's performance in Q4 and 2015, added Porges, who remains very upbeat on the company's overall Hepatitis C franchise for the near to medium term. He kept a $130 price target and Outperform rating on the shares. Analysts at UBS also remained positive on Gilead, writing that the company had a good quarter with its HIV franchise that resulted in a top-line beat despite the lower than expected Sovaldi sales. The firm said it remains bullish on the Harvoni launch and sees potential upside to estimates. UBS reiterated its Buy rating and $125 price target on Gilead shares. OTHERS TO WATCH: Other pharmaceutical companies offering and developing Hepatitis C treatments include Johnson & Johnson (JNJ) and Abbvie (ABBV). PRICE ACTION: In early trading, Gilead fell 2% to $111.25.
06:26 EDTINTCMicrosoft cooperates with Intel to offer subsidies for desktops,, DigiTimes says
Microsoft (MSFT) will cooperate with Intel (INTC) to offer subsidies to promote Windows 8.1 with Bing for entry-level desktops and 18.5-inch non-touch-screen all-in-one PCs, reports DigiTimes. According to Taiwan-based supply chain makers, Microsoft is hoping the new solutions will held defend its market share with Google (GOOG) aggressively promoting its Chromebox among vendors. Reference Link
October 28, 2014
18:42 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVRTXVertex expects FY14 revenues $525M-$535M, consensus $551.82M
Subscribe for More Information
16:18 EDTVRTXVertex reports Q3 adjusted EPS (37c), consensus (62c)
Subscribe for More Information
13:09 EDTJNJOptions with increasing implied volatility
Subscribe for More Information
09:09 EDTMDTMedtronic initiates PERIGON pivotal trial
Subscribe for More Information
07:37 EDTCOVCovidien announces launch of ReliaTack device
Subscribe for More Information
07:21 EDTJNJCBI to hold a conference
Subscribe for More Information
07:19 EDTMDT, COVMB Venture Partners to hold a conference
Subscribe for More Information
October 27, 2014
12:41 EDTINTCMicrosoft developing software to run on ARM based servers, Bloomberg reports
Subscribe for More Information
07:38 EDTINTCCyber security start-ups hot with investors, including banks, FT says
Corporate venture arms have more than doubled their investment in cyber security start-ups over the last two years, according to Financial Times, citing data from CB Insights. While technology companies such as Google (GOOG), Intel (INTC) and Cisco (CSCO) are leading, the report notes that the venture capital units of Citibank (C), Wells Fargo (WFC) and General Electric (GE) have also been active investors in security start-ups. Reference Link
07:29 EDTJNJWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
07:23 EDTCOVAmerican College of Surgeons holds a conference
Subscribe for More Information
06:20 EDTINTCIntel to release Haswell-EX/EP4S in Q2, DigiTimes reports
Subscribe for More Information
06:12 EDTINTCIntel to see strong shipment growth for Education Tablets, DigiTimes reports
Subscribe for More Information
October 24, 2014
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
06:32 EDTJNJJohnson & Johnson found 'not liable' in all-metal hip implant suit, WSJ reports
Subscribe for More Information
October 23, 2014
10:01 EDTBSXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:58 EDTJNJStocks with implied volatility below IV index mean; XLNX JNJ
Subscribe for More Information
05:33 EDTBSXBoston Scientific upgraded to Neutral from Sell at Goldman
Subscribe for More Information
October 22, 2014
17:50 EDTJNJBavarian Nordic announces expanded collaboration with Janssen on MVA-BN
Bavarian Nordic A/S announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to expand the collaboration announced earlier to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
14:17 EDTBSXBoston Scientific upgraded to Buy from Hold at Benchmark Co.
Price target $15.
09:21 EDTBSXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
08:43 EDTBSXBoston Scientific hasn't changed strategy in selling Synergy in Europe
Subscribe for More Information
08:25 EDTBSXBoston Scientific sees foreign exchange to be $55M headwind in FY14
Subscribe for More Information
08:18 EDTINTCVCE to become an EMC company
Subscribe for More Information
08:16 EDTBSXBoston Scientific 'well ahead' of delivering EPS, revenue expectations
Subscribe for More Information
07:52 EDTINTCIntel recent weakness a buying opportunity, says Jefferies
Subscribe for More Information
07:21 EDTMDTU.S. DHS investigates medical gear for potential cyber defects, Reuters says
Subscribe for More Information
07:07 EDTBSXBoston Scientific raises FY14 adjusted EPS to 81c-83c from 79c-83c
Subscribe for More Information
07:06 EDTBSXBoston Scientific sees Q4 adjusted EPS 20c-22c, consensus 21c
Subscribe for More Information
07:05 EDTBSXBoston Scientific reports Q3 adjusted EPS 20c, consensus 20c
Subscribe for More Information
06:44 EDTINTCIntel may face challenges over CPU product line in 2Q15, DigiTimes reports
Subscribe for More Information
06:26 EDTINTCIntel Capital announces investments from China Smart Device Innovation Fund
Subscribe for More Information
05:37 EDTVRTXVertex approval could add 500 more patients, says Piper Jaffray
Subscribe for More Information
05:31 EDTJNJJohnson & Johnson announces commitment to speed Ebola vaccine development
Subscribe for More Information
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administrationís Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:35 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
12:37 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
09:52 EDTCOV, MDTCovidien rises after Medtronic maintains merger date language
Shares of Covidien (COV) are rising in early trading after Medtronic (MDT), in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of the Irish drugmaker, left its language regarding the expected closing date unchanged. WHAT'S NEW: In its most recent filing, Medtronic again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived." ANALYST REACTION: Research firm BTIG says Medtronic's amended regulatory filing on the Covidien transaction increases the firm's confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. WHAT'S NOTABLE: AbbVie (ABBV) last night confirmed that the company and Shire (SHPG), another Irish domiciled drugmaker, agreed to terminate their proposed merger. AbbVie said its decision was based upon its assessment of the September 22 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a "uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions." AbbVie continued that the Treasury notice "introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes" and the stated intention of the department to continue to revise tax principles to further impact such "tax inversion" transactions. AbbVie noted that it has agreed to pay Shire a break fee of approximately $1.64B due to the deal falling through. PRICE ACTION: In early trading, shares of Covidien trading in New York rose 4% to $88.86, Medtronic advanced 1% to $64.57, Shires gained 0.7% to $185.82 and AbbVie added 1.4% to $55.16.
09:43 EDTMDT, COVAmended filing increases confidence in Covidien deal at BTIG
BTIG says Medtronic's (MDT) amended regulatory filing on the Covidien (COV) transaction increases its confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. Shares of Covidien are up 3% to $88.11 in early trading.
09:11 EDTMDT, COVMedtronic keeps language unchanged on merger closing date
Medtronic in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of Covidien (COV) left the language unchanged around the expected closing date. The company again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived."
09:03 EDTBSXBoston Scientific receives FDA and CE Mark approvals for CoverEdge leads
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
06:15 EDTINTCIntel may stop providing subsidies for mobile solutions, DigiTimes reports
Intel may stop providing subsidies for mobile device solutions to eliminate loses from the business, reports DigiTimes. According to sources from PC players, however, Intel is likely to continue offering subsidies to some of its larger clients, like Asustek Computer, through different methods in order to maintain orders. Reference Link
October 20, 2014
13:40 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
08:16 EDTBSXBoston Scientific initiates PLATINUM Diversity trial
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:20 EDTBSX, MDTInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:12 EDTCOV, MDTCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTBSXAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 17, 2014
16:55 EDTINTC, JNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
12:35 EDTCOVCovidien puts active on wide price movement
Covidien October 82, December 70 and January 75 puts are active on total put volume of 8K contracts (1K calls). November put option implied volatility is at 60, January is at 40, April is at 42; compared to its 26-week average of 25 according to Track Data. Active put volume suggests traders taking positions for large price movement.
10:51 EDTCOVOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTCOV, JNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use